Home › Idiopathic Pulmonary Fibrosis › NCT06323876
The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis
Who can join
Ages 40 to 101 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. ≥ 40 years of age 2. Diagnosed with IPF according to 2018 ATS/ERS/JRS/ALAT confirmed by the enrolling investigator 3. Signed informed consent Exclusion Criteria: 1. Pregnancy or planning to become pregnant 2. Women of childbearing potential not willing to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \<1% per year during study participation\* 3. Significant medical, surgical or psychiatric illness that in the opinion of the investigator would affect subject safety or potential to complete the research study * A woman is considered to be of childbearing potential if she is post-monarchical, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
About the study
This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available.
What is being tested
- HRCT (diagnostic test)
- Blood Draw (diagnostic test)
Sponsor: University of Virginia · Participants: 160 · Started: Jun 20, 2024
Contact the study team
- Roselove Nunoo-Asare · Phone: 4342436074
Official record on ClinicalTrials.gov — NCT06323876
Locations in the U.S.
| Virginia | University of Virginia, Charlottesville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.